Maltodextrin May Be a Promising Treatment Modality After Near-total Pancreatectomy in Infants Younger Than Six Months with Persistent Hyperinsulinism: A Case Report

What is already known on this topic? Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in newborns and infants. While several medical treatment agents are used to treat infants with CHI, hypoglycemia management has been quite difficult to date. What this study adds? In those cases with CHI, maltodextrin addition in the early period enables us to achieve more stable serum glucose. Maltodextrin addition also shortens the patient's discharge period, prevents complications, and protects the patient from treatment side effects. Continuous glucose monitoring systems help to manage the patients' follow-ups more efficiently in this group. Persistent hypoglycemia in infants with congenital hyperinsulinism (CHI) can be challenging in approximately half of these cases, even after undergoing a near-total pancreatectomy. While maltodextrin has been recommended in the nutritional management of CHI cases younger than six months, information regarding its efficacy in managing hypoglycemia are not yet clear. Here, we present a male infant with CHI who experienced persistent hypoglycemia even after undergoing a near-total pancreatectomy and despite multiple medical treatments. The infant's hypoglycemic episodes were successfully controlled by adding maltodextrin to his diet. Keywords: Congenital hyperinsulinism, ABCC8 gene, maltodextrin, near-total pancreatectomy, continue glucose monitoring systems